An interesting new paper in Cancer has offered us a sophisticated assessment of the effects of a diagnosis of and treatment for cancer on employment and income of all adults (aged 18 and older) and of adults in their prime working years (aged from 25 and 64). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Diagnosis, economics, employment, financial, toxicity, Treatment | 2 Comments »
There’s a new paper in an open-access journal called eCancer Medical Science that is asking a really tough question about links between unemployment and risk for prostate cancer mortality in the European Union nations. … READ MORE …
Filed under: Uncategorized | Tagged: economics, health, national, risk, unemployment | 1 Comment »
As some of our regular readers will be aware, a new form of cancer therapy known as “chimeric antigen receptor T-cell” therapy (often known as CART or CAR-T) is currently in advanced stages of development. … READ MORE …
Filed under: Drugs in development | Tagged: CAR-T, cost, drug, economics, new, Treatment | 2 Comments »
A new study by Goldman et al. just published in the journal Health Affairs suggests that, “Delayed aging could increase life expectancy by an additional 2.2 years, most of which would be spent in good health.” … READ MORE …
Filed under: Uncategorized | Tagged: aging, economics, risk | Leave a comment »
Luke Timmerman is a nationally respected health care journalist who specializes in writing about new healthcare technologies and writes regulary for an online business web site called Xconomy.com. Recently he took a tour of the new, $152 million ProCure proton beam radiation facility in Seattle. Click here to get his take.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: economics, proton, radiation, technology | 3 Comments »
Luke Timmerman is a journalist who specializes in the life sciences and writes for an on-line magazine called Xconomy out on the West Coast. He is well known for writing bluntly about issues that many members of the media have little real interest in addressing. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk | Tagged: cost, economics, value | 7 Comments »
In an article on KevinMD.com, Dr. Kelly Wright asks readers why everyone isn’t quite as excited about robot-assisted surgery as one might think they should be, given the plethora of information about the increasing use of robots in many known forms of surgery — prostate cancer included. … READ MORE …
Filed under: Management, Treatment | Tagged: cost, economics, radical prostatectomy, robot-assisted | Leave a comment »
Craig Turner, MD, practices urology in Portland, Oregon, and for the past 6 years or so he has been carrying out laparoscopic radical prostatectomies with the help of a da Vinci robot … but he doesn’t seem to think this has made him a better prostate cancer surgeon. … READ MORE …
Filed under: Management, Treatment | Tagged: care, economics, outcome, quality, RALP, technology | 1 Comment »
A study of prostate cancer treatments provided to economically disadvantaged men with relatively advanced forms of prostate cancer (compared to the average in the US today) suggests that where they were treated had at least as much (and probably more) impact on their treatment as their actual clinical condition. READ MORE …
Filed under: Management, Treatment | Tagged: disadvantaged patients, economics, IMPACT | Leave a comment »
Some (maybe many) readers of this column are not going to like an article on the front page of the New York Times today. … READ MORE …
Filed under: Management, Treatment | Tagged: economics, reform | 6 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 